PZM21 is primarily researched for its potential applications in pain management. It is a selective agonist for the mu-opioid receptor, which is a key target for pain relief medications. Unlike traditional opioids, PZM21 is designed to minimize side effects such as respiratory depression and addiction, making it a promising candidate for safer pain treatment. Studies suggest that it may provide effective analgesia without the euphoric effects that contribute to opioid abuse. Additionally, its unique mechanism of action could lead to the development of new therapies for chronic pain conditions, offering an alternative to current opioid-based treatments. Research is ongoing to further explore its efficacy and safety profile in clinical settings.